Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMN in DHDDS-CDG
NCT07572825Phase 1Recruiting
- Start
- May 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nicotinamide mononucleotide in congenital disorder of glycosylation (CDG). Primary endpoint: Incidence of adverse events up to 12 months. Started May 2026; status: recruiting.
02
Drugs
nicotinamide mononucleotide
03
Conditions
congenital disorder of glycosylation (CDG)
Beyond the preview
Go deeper on NCT07572825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572825.